In the phase IIA study was developed by company AbbVie ABBV drug-3373 demonstrated a positive effect on disease activity in patients with rheumatoid arthritis. A new drug is a conjugated monoclonal antibody with the drug (ADC) consisting of an inhibitor of tumor necrosis factor (TNF) and patented modulator of glucocorticoid receptor (GRM).
The primary endpoint of the study was change in disease activity index in 28 joints with determination of C-reactive protein (DAS28-CRP) from baseline to 12 weeks. To assess the effectiveness of the new tool were compared the data obtained in the study of drug ABBV-3373, and the results, sobrando in previous studies adalimumab. It was also compared data obtained in the study of drug ABBV-3373, and the results of current and previous studies adalimumab.
The results of both comparisons showed statistically significant superiority of the new therapy over adalimumab. In addition, measuring the level of cortisol in blood serum during 12 weeks show that the ABBV drug-3373 did not exert systemic effects associated with the glucocorticoids.
Developed by the drug company AbbVie ABBV-3373 is an experimental ADC consisting of the latest modulator of glucocorticoid receptor (GRM) associated with adalimumab influencing TNF mediated signaling pathways involved in the development of inflammation through delivery of corticosteroids directly to the activated immune cell expressing associated with membrane TNF. This ADC was designed for targeted effects on activated immune cells, causing a significant decrease in inflammation and minimizing systemic side effects associated with the glucocorticoids.